Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Admission serum sodium and osmolarity are not associated with the occurrence or outcomes of acute respiratory distress syndrome in critically ill

Heyi Li, MD,⁎, Shailesh Bihari, PhD, Shailesh Bihari, PhD, Timothy Weister, MSN, RN, Allison LeMahieu, MS, Rahul Kashyap, MBBS, Sarah Chalmers, MD, Amos Lal, MBBS, Andrew Bersten, MBBS, MD, Ognjen Gajic, MD

A R T I C L E   I N F O

Keywords:
ARDS
Acute lung injury
Hypernatremia
Hyperosmolarity
Critical care

A B S T R A C T

Background: Previous studies suggested that hypernatremia or hyperosmolarity may have protective effects in lung injury. We hypothesized that hypernatremia and/or hyperosmolarity would prevent ARDS.

Design: Retrospective cohort study of all admissions at medical, surgical, and multidisciplinary intensive care units in Mayo Clinic, Rochester from the year of 2009 to 2019. The occurrence of ARDS was identified using a validated computerized search strategy. The association between serum sodium/osmolarity and the occurrence of ARDS was analyzed using a multivariable logistic regression model. The relationship between serum sodium/osmolarity and outcomes of ARDS was analyzed using linear and logistic regression models.

Results: Among 50,498 patients, the serum sodium level on admission did not have a significant association with the occurrence of ARDS, with an adjusted odds ratio of 0.95 [95% CI (0.86, 1.05)]. There was no significant association between calculated serum osmolarity and the occurrence of ARDS, with an adjusted odds ratio of 1.03 [95% CI (1.00, 1.07)]. 1560 patients developed ARDS during the ICU stay. Their serum sodium level and osmolarity level did not have a significant association with their outcomes.

Conclusions: Admission serum sodium or serum osmolarity were not associated with the occurrence or outcomes of ARDS in ICU.

© 2022 Elsevier Inc. All rights reserved.

1. Introduction

Acute Respiratory Distress Syndrome (ARDS) is reported to occur in around 5–10% of critically ill patients and is associated with high mortality and morbidity [1,2]. The current treatment strategy is largely supportive, and very few therapeutic interventions have demonstrated outcome benefits. Meanwhile, a large body of literature has demonstrated that ARDS is a preventable condition by identifying the key elements of ARDS prevention, including lung-protective ventilation, early reassessment of non-invasive ventilation, standard aspiration precautions, adequate antimicrobial treatment and infection source control, optimal fluid management, and restrictive transfusion [3]. A scoring system of predisposing conditions and risk modifying factors of lung injury, the Lung Injury Prediction Score (LIPS), was derived from a multicenter observational cohort and demonstrated satisfactory validity in predicting lung injury risk in hospitalized population [4,5]. Therefore, recent research efforts on ARDS have been re-directed towards the prediction and prevention of this devastating complication of many critical illnesses [6].

The lung-protective effect of hypernatremia and hyperosmolarity has been hypothesized based on observational and experimental studies. Large cohort studies indicated that hypernatremia and
hyperosmolarity during the first 24 h of intensive care unit (ICU) stay were associated with worse outcomes in the general critically ill population, however, the association was not seen in the subgroup with respiratory diagnoses [7-9]. These findings suggested that hypernatremia or hyperosmolarity may have lung-protective effects in the critically ill. On this basis, many animal studies were conducted and detected lung-protective effects of hypernatremia or hyperosmolarity. Bihari and colleagues reported induced hypernatremia, created by infusing hypertonic saline, mitigated lung injury in an animal model. Similarly, more preclinical data showed that hyperosmolar infusion attenuated lung injury in various lung injury animal models, created by hemorrhagic shock [10-12], aspiration [13], intratracheal acid [13], or infection [14]. The protective effect of induced hypernatremia in moderate-to-severe ARDS was also demonstrated in a prospective clinical trial [15].

The hypothesized lung-protective effect of hyperosmolarity remains unproven in large-scale clinical settings. Thus, we have designed this study to retrospectively investigate whether sodium level and calculated osmolarity level upon admission to the ICU are associated with the occurrence rate or outcomes of ARDS. We hypothesized that a higher serum sodium level or higher calculated serum osmolarity within 24 h after ICU admission would be associated with 1) a lower occurrence rate of ARDS in patients at risk of ARDS and 2) favorable outcomes in patients who developed ARDS.

2. Methods

The study was approved by Mayo Clinic Institutional Review Board (Approval No. 13–008906, Title: ‘Does Serum Osmolarity Affect Outcomes of Patients with Acute Lung Injury?’. Approved on 12/4/2013). All patients provided informed consent allowing their medical records reviewed for research purposes. All research activities were in accordance with the ethical standards of the Mayo Clinic ethics committee on human experimentation and with the Helsinki Declaration of 1975.

2.1. Study population

This is a retrospective cohort study of adult patients admitted to the medical, surgical, and multidisciplinary ICUs at two hospitals in the Mayo Clinic Health System from January 1, 2009, to January 1, 2019. Our inclusion criterion was adult patients with age ≥ 18 years old. The exclusion criterion was patients who did not provide authorization for use of their health records. Jail or prison detainees were also excluded according to Minnesota Research Authorization Regulations. Only the first ICU admission was included for review if a patient had more than one ICU admissions during one hospitalization.

2.2. Data collection

The diagnoses, key events in the clinical course, laboratory tests, respiratory parameters, the severity of illness (represented by The Acute Physiology and Chronic Health Evaluation, APACHE III score), and outcomes were collected from the EHR. The definitions of the collected data items are listed in Supplemental Table 1. The first available serum sodium value and the most extreme sodium value within 24 h after ICU admission were used for analysis. The most extreme sodium value was the value with the largest deviation from the laboratory normal range (135–145 mmol/L). All values documented in the EHR were considered true values and we did not exclude ‘outliers’. The first available sodium, urea, and glucose values within 24 h after ICU admission were used for the calculation of serum osmolarity.

2.3. Computable phenotyping of ARDS

An EHR-based computable phenotyping strategy to identify ARDS has been previously published [16]. According to this rule-based search strategy, physicians’ judgement, if available, are fully acknowledged. All patients who had a clinical diagnosis of ARDS after ICU admission were identified. A clinical diagnosis of ARDS was defined as ICD-9 code 518.52, or ICD-10 code J80, or having ‘ARDS’ or ‘acute respiratory distress syndrome’ documented in the clinicians’ notes. In addition, for patients who did not have a clinical diagnosis of ARDS during the ICU admission, automatic EHR searching was applied. ARDS was identified if all these criteria were met:

(1) PaO2/FiO2 ratio ≤300.

(2) PEEP ≥5 cm H2O on invasive or noninvasive mechanical ventilation.

(3) Bilateral infiltrates on chest radiographs.

(4) The presence of at least one risk factor for ARDS (sepsis/septic shock, pneumonia, pancreatitis, trauma, aspiration, multiple transfusion, drug overdose, and shock) ≤7 days prior to the onset of 1), 2), and 3).

(1), (2), (3) must be met concurrently.

The following screening was conducted to further increase the specificity of identifying ARDS. ARDS risk factors (i.e., sepsis/septic shock, pneumonia, aspiration, pancreatitis, trauma, drug overdose, shock, and multiple transfusions) were searched for in the health records. Among cases without known ARDS risk factors, those with cardiogenic pulmonary edema, cardiogenic shock, or acute decompensated heart failure were excluded. According to previous ARDS cohort creation exercise, 28% of ARDS cases were documented by clinicians, when the computable phenotyping strategy based on the Berlin definition was used as gold standard [16].

2.4. Statistical analysis

Patient characteristics were summarized descriptively with median (Interquartile range, IQR) for continuous variables and frequency counts and percentages for categorical variables. In the first analysis, the relationship between sodium/osmolarity and the occurrence of ARDS was assessed using univariate and multivariable logistic regression. The multivariable models adjusted for admission ICU and lung injury prediction score (LIPS) using restricted cubic splines. The assumption of a linear function form was assessed by comparing model fit to a version using restricted cubic splines. The second analysis assessed the relationship between sodium/osmolarity and outcomes of interest, among patients who developed ARDS in the ICU, using univariate and multivariable linear regression models with generalized estimating equations (GEE). Outcomes of interest were ICU-free days, ventilation-free days, and mortality within 28 days of ARDS diagnosis. The multivariable models adjusted for admission ICU, APACHE score, and PaO2/FiO2 ratio. A similar analysis considered the primary explanatory variable of most extreme sodium in the first 24 h of ICU admission. Patients who developed ARDS prior to ICU admission were excluded from the first analysis because the endpoint of the analysis was the occurrence of ARDS. Patients who developed ARDS prior to ICU admission were also excluded from the second analysis because the variable time lapse between ARDS recognition and ICU admission (i.e. the time of sodium/osmolarity collection) introduced uncontrollable confounding factors. Sodium values were analyzed on a scale of 10 mmol/L for the convenience of calculation and display. For example, an Odds Ratio of 0.88 means the odds of an event reduces to 0.88 times when the sodium level increases by 10 mmol/L. Similarly, calculated osmolarity values were analyzed on a scale of 10 Osm/L.

In the first analysis, data were missing for sodium and calculated osmolarity. Multiple imputations were used to handle missing data for these variables assuming data were missing at random. Twenty-five imputed datasets were created, analyses run on each and results pooled across imputations to account for uncertainty in missingness. In the second analysis data were missing for sodium, calculated osmolarity,
APACHE score, and PaO₂/FiO₂ ratio. Similar to the first analysis, multiple imputation was used and 25 imputed datasets were created. In all analyses two-tailed p-values of 0.05 or less were considered statistically significant. Data management and statistical analysis were performed in SAS Studio 3.8 (SAS Institute Inc., Cary, North Carolina).

3. Results

During the study period, 82,084 patients from medical, surgical and trauma ICUs met the screening criteria. 50,498 patients met the inclusion criteria (Table 1). Of these, 1,560 patients developed ARDS during the ICU stay (Fig. 1). Patients with new-onset ARDS during ICU admission had a 28-day mortality of 34%. Their 28-day ICU-free duration was 18.0 (IQR, 0.237) days, and their 28-day ventilator-free duration was 24.8 (IQR 21.3, 26.5) days.

The univariate analysis showed that serum sodium level upon ICU admission was associated with a decrease in the occurrence of ARDS [OR 0.88 (95% CI 0.80, 0.98; p-value = 0.016]. However, after adjustment, serum sodium level was not associated with a decrease in the occurrence of ARDS [aOR 0.95, 95% CI (0.86, 1.05); p-value = 0.310]. Similarly, the univariate analysis assessing the relationship between calculated serum osmolarity upon ICU admission and the occurrence of ARDS was significant [OR 1.10, 95% CI (1.06, 1.14); p-value < 0.001], but after adjustment the association was no longer statistically significant [aOR 1.03, 95% CI (1.00, 1.07); p-value = 0.085] (Table 2).

Among the patients who developed ARDS during the ICU stay, the first serum sodium level upon admission did not have a significant association with ICU-free days [adjusted estimated difference 0.08 days, 95% CI (−0.85, 1.02), p = 0.859], ventilator-free days [adjusted estimated difference −0.02, 95% CI (−0.62, 0.58), p = 0.950], or 28-day mortality [aOR 1.02, 95% CI (0.84, 1.24), p = 0.810]. The association remained insignificant when the most extreme sodium values during the first 24 h of ICU stay were used for analysis. In addition, there was no significant association between the calculated serum osmolarity and the outcomes of ARDS [adjusted estimated difference in ICU-free days −0.26, 95% CI (−0.63, 0.12), p = 0.177; adjusted estimated difference in ventilator-free days −0.05, 95% CI (−0.28, 0.19), p = 0.705; aOR of 28-day mortality 1.07, 95% CI (0.99, 1.15), p = 0.112] (Table 3).

4. Discussion

This retrospective cohort study suggested that the sodium level or calculated osmolarity level during the first 24 h of ICU admission did not have a significant association with the occurrence rate of ARDS during the following ICU stay. Among the patients who developed ARDS during ICU admission, hypernatremia or hyperosmolarity were not associated with a difference in their clinical outcomes.

Hypernatremia and hyperosmolarity are common in critically ill patients. There are a wide variety of causes, including poor oral intake, renal dysfunction, or iatrogenic factors such as the use of diuretics or sodium-containing medications [17]. Their effects on lung injury remain controversial. Preclinical studies show that hypertonic fluid may mitigate lung injury by affecting both the innate and adaptive immunity reduction in lung injury [18]. Hypertonic saline solution affects the release of cytokines [19,20], reduces neutrophil sequestration [11,14,21,22], and inhibits endothelial cell activation [23]. Another proposed lung-protective mechanism of hyperosmolarity is preventing an increase in permeability by reducing calcium influx through mechanosensitive calcium channel TRPV4 [24]. Other reported mechanisms include enhancing the lung capillary barrier [25], or lowering pulmonary vascular resistance therefore improving perfusion of ventilated regions of the lung [26]. On the contrary, Yagi and colleagues reported hyperosmolarity is a risk factor for increased extrapulmonary lung water [27] which could lead to worse respiratory outcomes [23].

In clinical settings, the hypothesized lung-protective effect of hypernatremia/hyperosmolarity has been tested in prospective clinical studies and remains controversial. A randomized trial comparing hypertonic to isotonic crystalloid fluid as prehospital resuscitation suggested that the hypertonic saline group had a lower incidence of respiratory distress syndrome, although statistically insignificant [28]. Another randomized trial studying the lung-protective effect of hypertonic saline in blunt trauma was stopped for futility after the second interim analysis and did not demonstrate a difference in ARDS-survival [29]. Empirically induced hypernatremia has suggested clinical improvement in patients with moderate-severe ARDS in a clinical trial [15], however, it is still unknown whether hypernatremia secondary to other reasons, such as care process or dehydration, has lung-protective effect. Considering that hypernatremia and hyperosmolarity were reported to be associated with worse outcomes in the general critically ill population [7–9], the absence of association between hypernatremia/hyperosmolarity and mortality in this study suggests that hypernatremia and hyperosmolarity may have protected the subgroup of ARDS patients from poor outcomes.

Our study has several strengths. First, this is the first large clinical cohort study that investigated the association between hypernatremia/hyperosmolarity and ARDS in the era of Berlin definition. Most of the previous studies on hyperosmolarity and lung injuries were conducted in trauma-induced organ injury models. In our cohort, we included patients from various types of ICUs, representing a comprehensive real-world critically ill population who were at risk of ARDS due to different predisposing conditions, such as sepsis, surgeries, transfusions, etc. Their ARDS risk was stratified by the lung injury prediction score, which enabled us to build regression models to assess the association between hypernatremia/hyperosmolarity and ARDS. Second, studying ARDS in observational cohorts is traditionally challenged by the well-known under-recognition of this syndrome in the extremely complex critical care setting. The clinical recognition rate remains low from 28.5% using AECC (American-European Consensus Conference) definition [30] as the gold standard to 28.4% using the Berlin definition as

| Characteristic                  | Patients with a sodium value less than the median value (N = 19,195) | Patients with a sodium level greater than or equal to the median value (N = 27,061) | First Sodium value missing (N = 4,242) |
|--------------------------------|-----------------------------------------------------------------------|--------------------------------------------------------------------------------|-------------------------------------|
| **Age, median (Q1, Q3)**       | 65.0 (53.0, 75.0)                                                     | 65.0 (52.0, 76.0)                                                             | 61.0 (43.0, 75.0)                   |
| **Gender, n (%)**              |                                                                       |                                                                              |                                     |
| Female                         | 8330 (43%)                                                            | 12,149 (45%)                                                                 | 1888 (45%)                         |
| Male                           | 10,865 (57%)                                                          | 14,911 (55%)                                                                 | 2354 (55%)                         |
| Missing                        | 0 (0%)                                                                | 1 (0%)                                                                       | 0 (0%)                             |
| **BMI, median (Q1, Q3)**       | 27.8 (23.8, 33.0)                                                     | 28.2 (24.1, 33.5)                                                            | 27.6 (23.6, 32.7)                  |
| **Type of ICU, n (%)**         |                                                                       |                                                                              |                                     |
| Medical ICU                    | 7249 (38%)                                                            | 10,182 (38%)                                                                 | 1444 (34%)                         |
| Medical/Surgical/Transplant ICU| 4882 (25%)                                                            | 5440 (20%)                                                                   | 966 (24%)                          |
| Surgical/Trauma ICU            | 7064 (37%)                                                            | 11,439 (42%)                                                                 | 1834 (43%)                         |
| **Lung Injury Prediction Score, median (Q1, Q3)** | 4.5 (2.5, 7.0)                                                       | 4.0 (2.0, 6.5)                                                                | 2.5 (1.0, 4.0)                     |

1. Median sodium level: 134.5 mmol/L.
the gold standard [16]. The application of a computable phenotyping strategy allowed us to identify all ARDS cases and avoid underdiagnosis. There are several limitations of the study. First, retrospective studies in the complex critical care setting are often affected by confounding factors. Thus, we adjusted the logistic regression models for admission reasons and lung injury risk to limit confounding biases. Similarly, the linear regression models were adjusted for admission reasons, APACHE score, and PO2/FiO2 ratio. Prospective trials are still needed to investigate whether manipulating osmolarity changes the outcomes of lung injury. Second, the single laboratory measurement we used for the analyses may not represent the dynamic trend of electrolytes that leads to fluid shift. As a supplement to the main analysis, the most extreme sodium values were entered into the model resulting in the same conclusion. Due to the retrospective nature of the study, we did not have the capacity to identify artifact values (or ‘outliers’). Third, this report only reflects an experience prior to the COVID-19 era.

Fig. 1. Among 50,498 admissions that met the inclusion criteria, 1,560 patients developed ARDS during the ICU stay.

Table 2
The association between sodium/calculated osmolarity and the occurrence of ARDS during ICU admission.

| Input variable of Regression models | Unadjusted | Adjusted |
|-----------------------------------|------------|----------|
| LOGISTIC REGRESSION               |            |          |
| OR 95% CI  p-value                | OR 95% CI  p-value |
| First ICU sodium value            |            |          |
| ARDS during ICU stay              | 0.88 (0.80, 0.98) 0.016 | 0.95 (0.86, 1.05) 0.310 |
| Calculated osmolarity ARDS during ICU stay | 1.10 (1.06, 1.14) <0.001 | 1.03 (1.00, 1.07) 0.085 |

The first ICU sodium value was analyzed on a scale of 10 mmol/L. For example, an Odds Ratio of 0.88 means the odds of the occurrence of ARDS reduces to 0.88 times when the sodium level increases by 10 mmol/L. The calculated osmolarity was analyzed on a scale of 10 Osm/L.

Table 3
The association between admission sodium/calculated osmolarity and the outcomes of ARDS during ICU admission.

| Input variable of Regression models | Unadjusted | Adjusted |
|-----------------------------------|------------|----------|
| REGRESSION MODELS                  |            |          |
| Estimate 95% CI  p-value           | Estimate 95% CI  p-value |
| First sodium ICU value            |            |          |
| ICU-free days                      | 0.32       | (−0.66, 1.31) 0.523 | 0.08       | (−0.85, 1.02) 0.859 |
| Ventilation-free days              | −0.07      | (−0.66, 0.51) 0.807 | −0.02      | (−0.62, 0.58) 0.950 |
| 28-day mortality                   | 0.95       | (0.78, 1.16) 0.643 | 1.02       | (0.84, 1.24) 0.810 |
| Calculated osmolarity              |            |          |
| ICU-free days                      | −0.57      | (−0.95, −0.19) 0.003 | −0.26      | (−0.63, 0.12) 0.177 |
| Ventilation-free days              | −0.04      | (−0.27, 0.19) 0.754 | −0.05      | (−0.28, 0.19) 0.705 |
| 28-day mortality                   | 1.12       | (1.04, 1.22) 0.003 | 1.07       | (0.99, 1.15) 0.112 |
| Most extreme sodium value in first 24 hours |            |          |
| ICU-free days                      | 1.26       | (0.20, 2.32) 0.020 | 0.57       | (−0.48, 1.61) 0.287 |
| Ventilation-free days              | 0.12       | (−0.51, 0.76) 0.698 | 0.17       | (−0.48, 0.82) 0.604 |
| 28-day mortality                   | 0.84       | (0.68, 1.03) 0.096 | 0.98       | (0.78, 1.21) 0.822 |

1 The estimates for ICU-free days are the estimated difference in days alive and days spent out of the ICU within 28 days from admission; patients who die have zero ICU-free days.
2 The estimates for Ventilation-free days are the estimated difference in days alive and days off ventilation within 28 days from admission.
3 The estimates for 28-day mortality are Odds Ratios.
4 The first ICU sodium value and the most extreme sodium value in the first 24 h were analyzed on a scale of 10 mmol/L.
5 Calculated osmolarity was analyzed on a scale of 10 Osm/L.
while ‘rapidly improving ARDS’ [31] consisted of a significant portion of the ARDS patients. Thus, the observed mechanical ventilation duration is shorter than that during the COVID-19 pandemic. The authors also attributed the short mechanical ventilation duration to persistent compliance to evidence-based care, such as lung-protective ventilation, conservative fluid management, daily assessment for weaning, and offering palliative care.

Overall, our study is the first large-scale clinical cohort study that investigated the potential association between admission sodium/osmolality levels and ARDS during ICU admission. The results did not support the manipulation of serum sodium/osmolality as a lung-protective measure at the early stage of critical illnesses.

Source of Funding

Mayo Clinic Rochester Critical Care Independent Multidisciplinary Program Research Subcommittee small grant funded this study for data retrieval and statistical support.

Author contributions

Funding acquisition and project administration: HL; Conceptualization: HL, AB, OG; Data Curation: KK, TW, HL; Formal Analysis and methodology: TW, HL, AL; Writing-original draft: HL; Writing-review & editing: OG, SC, AL, AB.

Consent for publication

All the authors give their authorization to publish the article.

Availability of data and materials

The data used for this research are available from the corresponding author on reasonable request and subject to Institutional Review Board guidelines.

Ethical approval and consent to participate

This study was reviewed and approved by the Institutional Review Board at Mayo Clinic, Rochester (IRB 13–008906). All research activities were in accordance with the ethical standards of the Mayo Clinic ethics committee on human experimentation and with the Helsinki Declaration of 1975. Informed consent was waived for patients with Minnesota research authorization.

Declaration of Competing Interest

All authors have disclosed that they do not have any conflicts of interest related to this study.

Acknowledgments

We thank the Anesthesia Clinical Research Unit for their help with electronic data abstraction.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jcrc.2022.154179.

References

[1] Zilberberg MD, Carter C, Lefebvre P, et al. Red blood cell transfusions and the risk of acute respiratory distress syndrome among the critically ill: a cohort study. Crit Care. 2007;11(3):1–9.

[2] Bellani G, Laffey JG, Pham T, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315(9):788–900.

[3] Beiler JR, Schoenfeld DA, Thompson BT. Preventing ARDS: progress, promise, and pitfalls. Chest. 2014;164(4):1102–13.

[4] Soto GJ, Kor DJ, Park PK, et al. Lung injury prediction score in hospitalized patients at risk of acute respiratory distress syndrome. Crit Care Med. 2016;44(12):2182.

[5] Gajic O, Dabbagh O, Park PK, et al. Early identification of patients at risk of acute lung injury: evaluation of lung injury prediction score in a multicenter cohort study. Am J Respir Crit Care Med. 2011;183(4):462–70.

[6] Festic E, Kor DJ, Gajic O. Prevention of ARDS. Curr Opin Crit Care. 2015;21(1):82.

[7] Shen Y, Cheng X, Ying M, et al. Association between serum osmolality and mortality in patients who are critically ill: a retrospective cohort study. BMJ Open. 2017;7(5):e015729.

[8] Bihari S, Prakash S, Peake SL, et al. ICU mortality is increased with high admission serum osmolality in all patients other than those admitted with pulmonary diseases and hyponatraemia. Respirology. 2017;22(6):1165–70.

[9] Bihari S, Peake SL, Bailey M, et al. Admission high serum sodium is not associated with increased intensive care unit mortality risk in respiratory patients. J Crit Care. 2014;29(6):948–54.

[10] Murao Y, Loomis W, Wolf P, et al. Effect of dose of hypertonic saline on its potential to prevent lung tissue damage in a mouse model of hemorrhagic shock. Shock. 2003;20(1):29–34.

[11] Rizoli SR, Kapus A, Fan J, et al. Immunomodulatory effects of hypertonic resuscitation on the development of lung inflammation following hemorrhagic shock. J Immunol. 1998;161(11):6208–16.

[12] Shi HP, Deitch EA, Lu G, et al. Hypertonic saline improves intestinal mucosa barrier function and lung injury after trauma-hemorrhagic shock. Shock. 2002;17(6):496–501.

[13] Rabinovici R, Vernick J, Hillelagas L, et al. Hypertonic saline treatment of acid aspiration-induced lung injury. J Surg Res. 1990;60(1):176–80.

[14] Pascual JL, Khwaja KA, Ferri LE, et al. Hypertonic saline resuscitation attenuates neutrophil lung sequestration and transmigration by diminishing leukocyte-endothelial interactions in a two-hit model of hemorrhagic shock and infection. J Trauma Acute Care Surg. 2003;54(1):121–32.

[15] Bihari S, Prakash S, Dixon DL, et al. Induced hypernatremia in patients with moderate-to-severe ARDS: a randomized controlled study. Intensive Care Med Exp. 2021;9(1):1–12.

[16] Li H, Odeyemi YE, Weister TJ, et al. Rule-based cohort definitions for acute respiratory distress syndrome: a computable phenotyping strategy based on the Berlin definition. Crit Care Explor. 2021;3(6).

[17] Boom EJ, Betjes MG, Weigel J, et al. Hypernatremia in critically ill patients: too little water and too much salt. Nephrol Dial Transplant. 2008;23(5):1562–8.

[18] Scarpelini S, Rhind SG, Tien H, et al. Effects of hypertonic saline on the development of acute lung injury following traumatic shock. J Organ Dysfunt. 2008;4(2):95–105.

[19] Hatakanaka E, Shimmoto FM, Curi R, et al. Sodium chloride inhibits cytokine production by lipopolysaccharide-stimulated human neutrophils and mononuclear cells. Shock. 2007;27(1):32–5.

[20] Ochi H, Masuda J, Gimbrone MA. Hyperosmotic stimuli inhibit VCAM-1 expression in cultured endothelial cells via effects on interferon regulatory factor-1 expression and activity. Eur J Immunol. 2002;32(7):1821–31.

[21] Angle N, Hoyt DB, Coimbra R, et al. Hypertonic saline resuscitation diminishes lung injury by suppressing neutrophil activation after hemorrhagic shock. Shock (Augusta, Ga). 1998;9(3):164–70.

[22] Deitch EA, Shi HP, Feketeova E, et al. Hypertonic saline resuscitation limits neutrophil activation after trauma-hemorrhagic shock. Shock. 2003;19(4):328–33.

[23] Junger WG, Rhind SG, Rizoli SB, et al. Resuscitation of traumatic hemorrhagic shock patients with hypertonic saline without dextran-inhibits neutrophil and endothelial cell activation. Shock (Augusta, Ga). 2012;38(4):341.

[24] Bihari S, Dixon D-L, Lawrence MD, et al. Fluid-induced lung injury—role of TRPV4 channels. Pfliig Arch Eur J Physiol. 2017;469(9):1121–34.

[25] Saffdar Z, Wang P, Ichimura H, et al. Hypersalinity enhances the lung capillary barrier. J Clin Invest. 2003;112(10):1541–9.

[26] Powers Jr SR, Shah D, Ryon D, et al. Hypertonic mannitol in the therapy of the acute respiratory distress syndrome. Ann Surg. 1991;213(1):29–50.

[27] Yagi T, Kaneko T, Tsuruta R, et al. Global end-diastolic volume, serum osmolarity, and albumin are risk factors for increased extravascular lung water. J Crit Care. 2011;26(2):224; e9-24. e13.

[28] Mattoux KL, Maningas PA, Moore EE, et al. Prehospital hypertonic saline/dextran infusion for post-traumatic hypotension. The USA multicenter trial. Ann Surg. 1991;213(5):482.

[29] Bulger EM, Jurkovich GJ, Nathens AB, et al. Hypertonic resuscitation of hypovolemic shock after blunt trauma: a randomized controlled trial. Arch Surg. 2008;143(2):139–48.

[30] Heraeevich Y, Yilmaz M, Khan H, et al. Validation of an electronic surveillance system for acute lung injury. Intensive Care Med. 2009;35(6):1018–23. https://doi.org/10.1007/s00134-009-1460-1. published Online First: Epub Date.

[31] Schenck Jr, Oromendia C, Torres LL, et al. Rapidly improving ARDS in therapeutic randomized controlled trials. Chest. 2019;155(3):474–82.